CBP-1008-02

An Open-label，Multi-center, Phase Ia, Ib Study Evaluating the Safety, Tolerability, and Pharmacokinetic Profile of a Weekly Regimen of CBP-1008 for Injection in Patients with Advanced Solid Tumors Positive for FOLR1 and/or TRPV6 Expression and Expansion in Selected Indications